Novartis CEO Vas Narasimhan discusses the company's quarterly earnings as the drugmaker lifted profit guidance for a third ...

Novartis is one of the world's top pharmaceutical ... France, England, Italy, Russia and the US. By 1884, Bindschedler & Busch had transformed into a joint-stock company and was renamed ...

The "CC Chemokine Receptor Type 5 Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The CC ...

Healthcare: Novartis [NOVN.CH] -3.5% (Q3 results ... 09:00 (UK) Daily Baltic Dry Bulk Index. - 09:00 (RU) Russia announcement ...

Buccal Drug Delivery System market Size, Share, Revenue, Trends, and Drivers For 2024-2033. Buccal Drug Delivery System Market Size, Share, Revenue, Trends ...

Corporate updates: BP, Ferrovial, Lufthansa, Novartis and Santander are among companies reporting ... North Korean foreign ...

Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an ...

Oct 16 (Reuters) - Novartis (NOVN.S), opens new tab has lost a bid to keep a generic version of its top-selling heart failure drug Entresto off the U.S. market by blocking regulators from ...

Exactly three years after an initial FDA green light for the third-line treatment of leukemia, Novartis’ Scemblix has won an accelerated approval to treat newly diagnosed patients. Tuesday ...

Novartis has terminated a phase 2 trial of its SMURF1 inhibitor LTP001 in idiopathic pulmonary fibrosis (IPF) but will continue to advance the candidate in another indication. The Swiss drugmaker ...

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales of drugs like breast-cancer treatment Kisqali. The Swiss pharmaceutical ...

Truist highlights Novartis' strong balance sheet, which enables further bolt-on deals and share buybacks. Recent transactions primarily involve deals in the sub-$1 billion range, along with a few ...